GlassScriptPhysician profile
Toni O Pacioles
NPI 1396959995
$747.25
in general payments reported to CMS, 2019-2025
14 companies · $220 in 2025
The $220 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $55.45 · 2022: $82.41 · 2023: $116 · 2024: $86.94 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $329 · Education: $93.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $329.14 |
| Education | $93.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Histosonics, INC. | $141.88 | 2025 | |
| Pfizer INC. | $94.38 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $89.14 | 2019-2024 | Onureg, Reblozyl |
| Beigene USA, INC. | $85.55 | 2023 | Brukinsa |
| Galvanize Therapeutics, INC | $82.41 | 2022 | |
| Merck Sharp & Dohme LLC | $61.88 | 2024-2025 | Welireg |
| Astellas Pharma US INC | $42.54 | 2019 | |
| Tempus Ai, INC | $35.11 | 2024-2025 | Xt Cdx |
| Genentech USA, INC. | $29.99 | 2019-2023 | Tecentriq |
| Astrazeneca Pharmaceuticals LP | $24.12 | 2020 | |
| Novocure INC. | $16.75 | 2025 | Optune Lua (Novottf-200t) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.82 | 2019 | |
| Foundation Medicine, INC. | $15.63 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toni Pacioles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.